Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SS-BREX: Switching to brexpiprazole in schizophrenia and schizoaffective disorder
jRCTs031180015Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of brexpiprazole in schizophrenia and schizoaffective disorder, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Treatment continuation rate 1 at Week 12 of treatment with brexpiprazole. Started Dec 2018; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on jRCTs031180015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180015.